The question of cognitive decline as a result of MS is a serious one. If the accumulation of physical disability is a hallmark of the condition, its affect on cognitive dysfunction is not always so obvious. In fact, in a recent trial for Copaxone (glatiramer acetate) observing cognitive scores, the placebo group improved just as much as the Copaxone-treated group over two years. Perhaps 2 years was too short to see a difference, so a new study observed a group of MS'ers over TEN years.
Please click 'read more' to see the rest of the story...
The rest of this story is hosted at our sister site, Experience Project, run by the same team behind This is MS. Experience Project is 100% free, and you may read the rest of the article, vote for it if you like it, and submit your own news postings. It opens in a new window. Enjoy and please let us know if you like the new functions available to you!
Click to Read: Minimal Changes in Cognitive Function of Relapsing-Remitting MS'ers in a 10-year clinical trial.
